Summary Judgment Granted for SEROQUEL R Patent Litigation: related news

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL(R) (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca AZN today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL(R) (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca AZN today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL(R) (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL(R) (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN - News) today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL® (quetiapine fumarate) tablets in the US before SEROQUEL's patent expires in 2011. Since the Court granted AstraZeneca's motion for Summary Judgment of No Inequitable Conduct in its entirety, trial is unnecessary.

Privacy advocates marshal to fight copyright regime

A s r l a i t r e s r i e r v d r a d o s m r r u s r g a i g p o i h t e o e f l S o y i h l b y v r p o o e n w n e n t o a t a e g e m n t a a m t e t b i h n w n e l c u l r p r y i h s n o c m n r g m t c a k o n n l c r n c o n e f i i g n p r c .

AstraZeneca granted summary judgment in Seroquel patent litigation

AstraZeneca has announced that the US District Court of New Jersey has granted the company's motion for summary judgment of no inequitable conduct.

AstraZeneca says Summary Judgment Granted for SEROQUEL Patent Litigation - Quick Facts

(RTTNews) - AstraZeneca (AZN: News, Chart, Quote ) announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct.

Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges

PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex(R) product. Separately, Barr Laboratories entered into a Settlement Agreement and a Supply Agreement to resolve the patent litigation regarding Boehringer Ingelheim's Aggrenox(R) product and Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, entered into a Co-Promotion Agreement with Boehringer Ingelheim relating to Aggrenox(R).

Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges

MONTVALE, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex(R) product. Separately, Barr Laboratories entered into a Settlement Agreement and a Supply Agreement to resolve the patent litigation regarding Boehringer Ingelheim's Aggrenox(R) product and Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, entered into a Co-Promotion Agreement with Boehringer Ingelheim relating to Aggrenox(R).

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US District Court for the District of

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

Hier finden Sie Nachrichten zu Ihrem Suchbegriff - Sie können den Zeitraum angeben oder auch Suchbegriffe kombinierenErweiterte Suche |

Summary Judgment Granted for SEROQUEL(R) Patent Litigation

PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US District Court for the District of

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

ipernica says decision close on US patent

L s e i t l e t a p o e t a s r i n i m p r i a a s i a o g- w i e U P t n a d r d m r O f c d c s o a f c i g l n t y i p t w t t e o l 's e o d- a g s s f w r c m a y, r c e o p r t o , s o l c m b t e n o t e e r.

Midway Announces Mortal Kombat(R): Kollection(TM) Exclusively for PlayStation(R)2 System This FallMidway Announces Mortal Kombat(R): Kollection(TM) Exclusively for PlayStation(R)2 System This Fall (Graphic: Business Wire)

Special three-pack includes fan favorites: Mortal Kombat: Deception(R), Mortal Kombat: Armageddon(R) and Mortal Kombat: Shaolin Monks(R)

Midway Announces Mortal Kombat(R): Kollection(TM) Exclusively for PlayStation(R)2 System This FallMidway Announces Mortal Kombat(R): Kollection(TM) Exclusively for PlayStation(R)2 System This Fall (Graphic: Business Wire)

Special three-pack includes fan favorites: Mortal Kombat: Deception(R), Mortal Kombat: Armageddon(R) and Mortal Kombat: Shaolin Monks(R)

Midway Announces Mortal Kombat(R): Kollection(TM) Exclusively for PlayStation(R)2 System This FallMidway Announces Mortal Kombat(R): Kollection(TM) Exclusively for PlayStation(R)2 System This Fall (Graphic: Business Wire)

Special three-pack includes fan favorites: Mortal Kombat: Deception(R), Mortal Kombat: Armageddon(R) and Mortal Kombat: Shaolin Monks(R)

Midway Announces Mortal Kombat(R): Kollection(TM) Exclusively for PlayStation(R)2 System This FallMidway Announces Mortal Kombat(R): Kollection(TM) Exclusively for PlayStation(R)2 System This Fall (Graphic: Business Wire)

Special three-pack includes fan favorites: Mortal Kombat: Deception(R), Mortal Kombat: Armageddon(R) and Mortal Kombat: Shaolin Monks(R)

Activision Publishing Broadens Product Portfolio With Crash Bandicoot(R), Ice Age(R),...

Activision Publishing Broadens Product Portfolio With Crash Bandicoot(R), Ice Age(R), Spyro(R) and Two New Intellectual Properties Company to Streamline Vivendi Games' Studio Operations SANTA MONICA, Calif., July 28 /PRNewswire-FirstCall/ -- Further strengthening its foundation for future growth, Activision Publishing, Inc. (Nasdaq: ATVI) today announced that the company will broaden its product portfolio by adding Vivendi Games' multi-million unit selling properties Crash Bandicoot(R), Ice Age(R) and Spyro(R) to its roster of proven franchises. The company will also retain two new intellectual properties that are currently in development -- Prototype and a second game that has not yet been announced. Additionally, Activision Publishing will continue to support the Vivendi Games' catalogue including The Mummy: Tomb of the Dragon Emperor(T

Search took 0.28 seconds.